Dose dependent pharmacokinetics of midazolam. 1985

L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel

The pharmacokinetics of midazolam and 1-hydroxymethylmidazolam were investigated following oral administration of 7.5, 15 and 30 mg doses of midazolam in solution to 12 healthy subjects. Compared to the 7.5 mg dose, the Cmax and AUC parameters of both midazolam and 1-hydroxymethylmidazolam increased proportionally after the 15 mg dose and more than proportionally after the 30 mg dose. The t1/2 for midazolam remained relatively constant between the 7.5 and 15 mg doses whereas it increased slightly but significantly after the 30 mg dose. These data indicated that the pharmacokinetics of midazolam and 1-hydroxymethylmidazolam were linear between the 7.5 and 15 mg oral dose range. However, after the 30 mg dose, the systemic availability of midazolam and the AUC for 1-hydroxymethylmidazolam appeared to be greater than that anticipated from the lower doses, possibly due to saturation of midazolam first-pass metabolism. This is not expected to have any clinical significance under the conditions of therapeutic use.

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000777 Anesthetics Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. Anesthetic,Anesthetic Agents,Anesthetic Drugs,Anesthetic Effect,Anesthetic Effects,Agents, Anesthetic,Drugs, Anesthetic,Effect, Anesthetic,Effects, Anesthetic

Related Publications

L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
March 2023, Xenobiotica; the fate of foreign compounds in biological systems,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
January 1983, Pharmacology & therapeutics,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
January 1986, Journal of clinical pharmacology,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
December 1993, Critical care medicine,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
November 1977, European journal of clinical pharmacology,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
January 1986, European journal of clinical pharmacology,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
May 1987, British journal of clinical pharmacology,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
November 1997, Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
January 1981, Cancer chemotherapy and pharmacology,
L D Bornemann, and B H Min, and T Crews, and M M Rees, and H P Blumenthal, and W A Colburn, and I H Patel
May 1996, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!